Evidence has accumulated that adult tissues contain developmentally early stem cells that remain in a dormant state as well as stem cells that are more proliferative, supplying tissue-specific progenitor cells and thus playing a more active role in the turnover of adult tissues. Interestingly, evidence has accumulated in parallel that these most primitive, dormant, adult stem cells are regulated by epigenetic changes in the expression of certain parentally imprinted genes, a molecular phenomenon previously described for keeping primordial germ cells in a quiescent state. Specifically, the most primitive quiescent stem cells in bone marrow that can be committed to the hematopoietic lineage show erasure of imprinting at the Igf2–H19 locus, which keeps them in a quiescent state in a similar manner as primordial germ cells. Similar changes in expression of parentally imprinted genes may also play a role in the quiescence of dormant adult stem cells present in other non-hematopoietic tissues. However, this possibility requires further study.

**Keywords:** Adult stem cells, primordial germ cells, imprinted genes, Igf2–H19 locus, stem cell quiescence, tissue regeneration, tumorigenesis.
Introduction

Despite a vast amount of work, the hierarchy within the adult stem cell compartment is still incompletely understood. Various types of stem cells residing in postnatal tissues that possess more than one germline specification potential have been described [1–13]. The undisputed fact that adult tissues contain such cells gives rise to three important questions that we will discuss in this chapter.

The first question is related to the fact that the first stem cells specified in the developing embryo in both including rodents and humans are primordial germ cells (PGCs). Therefore, one could ask: How much germline potential is present in adult stem cells? This question is highly relevant to hematopoietic stem cells (HSCs), because there is an intriguing developmental link between specification and migration in the embryo of PGCs and in the origin of primitive and definitive HSCs [14–17]. Moreover, these cell populations also share several markers and respond to stimulation by sex hormones (SexHs) [18–21].

The second question to be answered is: Are some of the stem cells from the embryonic stage of development deposited into and reside in adult tissues in the quiescent state? This emerging concept suggests a developmental continuum in the stem cell compartment, beginning from the fertilized zygote to adult stem cells. If this is correct, then the end of organogenesis does not mean complete elimination of developmentally early stem cells from postnatal tissues. Such cells could survive in the adult body as a potential backup for tissue-committed stem cells and play a role in their turnover [22–24].

The third question is: Why do some developmentally early stem cells that express markers of pluripotency remain in a quiescent state in adult tissues, and why are they not able to form teratomas or complete blastocyst development? To address this question, we proposed that the most primitive developmentally early stem cells in adult tissues could be kept in a quiescent state, as in migrating PGCs, by changes in expression of certain parentally imprinted genes [25]. Proper expression of these genes is crucial for initiation of embryogenesis and cell proliferation [26]. By contrast, these genes are normally expressed in embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs), which enables these cells to complete blastocyst development and grow teratomas in vivo [25, 27].

Based on the aforementioned, we will discuss these three issues and present evidence that certain developmentally early stem cells, sharing several markers with PGCs and the epiblast, are kept in a quiescent state in adult tissues
by changes in expression of parentally imprinted genes. In particular, we will focus on bone marrow (BM)-residing stem cells.

**Question 1 – How Much Germline Potential Is Present in Adult Bone Marrow Stem Cells?**

The first stem cells that become specified in the earliest stages of embryogenesis in the epiblast of the post-implantation blastocyst are PGCs [28, 29]. The epiblast is a precursor of the entire embryo proper, and PGCs are precursors of gametes that pass genetic information, encoded in parental DNA, and mitochondria to the next generation. These cells, endowed with developmental totipotency, become specified in the proximal part of the epiblast and, after specification, leave the embryo proper and migrate to the extra-embryonic mesoderm, where they begin to amplify, make a turn, and again enter the embryo proper through the so-called primitive streak. While continuing to amplify in number, the PGCs then migrate toward the genital ridges [30], where they settle and initiate gametogenesis. On their migratory route through the embryo proper toward the genital ridges they cross the part of the embryo called the aorta–gonado–mesonephros (AGM) region [31].

As shown in Figure 1, the developmental route of PGCs overlaps with the emergence of the first primitive HSCs in time and space—first in the so-called blood islands at the bottom of the yolk sac and later with the emergence of definitive HSCs in the AGM region of the developing embryo proper. Both PGCs and HSCs are highly migratory stem cells, and it is very likely that some of the PGCs, while migrating in the extra-embryonic mesoderm, first give rise to hemangioblasts, which are precursors for both primitive hematopoietic cells and endothelial progenitors. Subsequently, while they migrate in the embryo proper towards the genital ridges, some of them become specified into definitive HSCs detectable in the hemangiogenic endothelium of the dorsal aorta [31–34].

Based on this close developmental overlap between PGCs and HSCs, one can ask how much germline potential is in HSCs, and, vice versa, whether germline-derived cells share genes involved in the development of both lineages. In fact, mounting evidence has accumulated that HSCs are responsive to several pituitary and gonadal SexHs and share certain molecular markers typical of germ development, such as the Sall4 transcription factor [35, 36]. On the other hand, germline-derived cells express the erythropoietin receptor, which is well known to be expressed by hemangioblasts and cells from the erythroid lineage. Accordingly, we demonstrated that human and murine
Figure 1 Migration of PGCs and the developmental origin of primitive and definitive hematopoiesis. The specification of the first primitive HSCs in the yolk sac blood islands as well as the origin of definitive HSCs in the aorta–gonado–mesonephros (AGM) region are chronologically and anatomically correlated with the developmental migration of primordial germ cells in extra- and intra-embryonic tissues. For reasons of simplicity, the developmental difference between the times when primitive and definitive hematopoiesis are initiated is not reflected by embryo maturation.

germline-derived teratocarcinoma cell lines as well as ovarian cancer cell lines express functional erythropoietin receptors and respond to erythropoietin by chemotaxis, increased adhesion, and phosphorylation of MAPKp42/44 and AKT [37].

On the other hand, to better address the potential role of SexHs in the development of HSCs, we performed a series of experiments to address the influence of follicle-stimulating hormone, luteinizing hormone, progesterone, androgens, estrogens, and prolactin on murine hematopoiesis [21]. We found that 10-day administration of each of the SexHs evaluated in this study directly stimulated expansion of HSCs in BM, as measured by an increase in the number of these cells (∼2–3x), an observation supported by enhanced bromodeoxyuridine (BrdU) incorporation into the nuclei of these cells. The percentage of BrdU⁺ Sca-1⁺ Lin⁻ CD45⁺ HSCs, depending on the type of SexH employed, increased from ∼25% to 45–60%. This stimulatory effect
paralleled an increase in the number of clonogenic BM progenitors (∼2–3x). We also observed that murine Sca-1+ Lin− CD45+ HSCs express pituitary and gonadal SexH receptors and respond to stimulation by phosphorylation of MAPKp42/44 and AKT. We also observed that administration of SexHs accelerated the recovery of peripheral blood (PB) cell counts in sublethally irradiated mice and slightly mobilized HSCs into circulation. Finally, in direct in vitro clonogenic experiments on purified murine progenitor cells, we observed a stimulatory effect of SexHs on clonogenic potential if added with suboptimal doses of the colony stimulating factors CFU-Mix, BFU-E, CFU-Meg, and CFU-GM. Thus, our data indicate that pituitary- and gonadal-secreted SexHs directly stimulate the expansion of stem cells in BM [21].

Finally, in further support of this developmental link between the germline and hematopoiesis, it is important to mention that several papers have described the sharing of chromosomal aberrations between germline tumors and leukemias or lymphomas, which suggests their common clonal origin [17, 38–40]. More direct evidence has also demonstrated that murine PGCs isolated from embryos, murine testes, and teratocarcinoma cell lines can be specified into hematopoietic stem/progenitor cells [15–17, 41, 42]. These findings all support a close developmental relationship between the germline and hematopoiesis.

**Question 2 – Do Early-Development Stem Cells Reside in Adult Tissues?**

A decade ago the concept of stem cell plasticity or stem cell transdifferentiation was proposed [6, 43–48]. Based on this idea, tissue-committed stem cells, such as HSCs, could change their fate and differentiate into stem cells for other lineages, for example, cardiac stem cells. This concept however, did not stand up to critical examination, and other explanations for why some degree of chimerism has been observed in various tissues after transplantation of bone marrow cells have been proposed. One of these alternative explanations involves the phenomenon of cell fusion [49–52].

By contrast, my team from the beginning proposed that stem cell plasticity could be explained by the fact that the adult BM contains early-development stem cells, and we succeeded in isolating from adult murine BM cells that were slightly smaller than erythrocytes and that expressed pluripotency markers such as Oct-4 and Nanog, which we called very small embryonic-like stem cells (VSELs) [24, 53]. Meanwhile, in the past several years, various cells endowed with multi-tissue differentiation potential have been identified by
other investigators in adult murine or human BM and, depending on the
methods for how they were isolated, assigned different names, such as spore-
like stem cells [54], multipotent adult stem cells (MASCs) [1], mesenchymal
stem cells (MSCs) [55], multine lineage-differentiating stress-enduring (Muse)
cells [56], multipotent adult progenitor cells (MAPCs) [4], unrestricted
somatic stem cells (USSCs) [3], marrow-isolated adult multine lineage-inducible
(MIAMl) cells [2], or multipotent progenitor cells (MPCs) [1, 57]. Interest-
estingly, in addition to the cells listed above, adult bone marrow has been
also postulated to contain hemangioblasts [58] as well as cells that retain the
potential to differentiate into gametes (Table 1) [59, 60].

This has created nomenclatural chaos, and probably several of these stem
cells described as separate entities are in fact overlapping cell populations.
We envision that, most likely, VSELs are at the top of the hierarchy of all
of these various overlapping populations of stem cells that are endowed with

| Table 1 | Selected publications from other authors indicating that stem cells endowed with germline potential reside in non-gonadal tissues, such as adult bone marrow and skin |
|----------------|---------------------------------------------------------------|
| Cells Endowed with Germline Markers as They Were Originally Described in the Literature | Reference |
| Stem cells with germline potential isolated from newborn mouse skin – Oct-4<sup>+</sup> cells isolated by FACS from Oct-4–GFP mice, which are able to give rise in vitro and in vivo to early oocytes. Similar cells were also identified in newborn porcine skin. | [67] |
| Multipotent stem/stromal cells isolated from porcine skin – Oct-3/4<sup>+</sup>, Nanog<sup>+</sup> Sox-2<sup>+</sup> cells isolated from porcine skin and adipose tissue and able to differentiate into oocyte-like cells. | [68] |
| SSEA-1<sup>+</sup> murine BM cells – Isolated from murine BM by anti-SSEA-1 immunomagnetic beads. In the presence of bone morphogenetic protein 4 (BMP4), these cells differentiate into Oct-4<sup>+</sup> Stella<sup>+</sup> Mvh<sup>+</sup> gamete precursors. | [69] |
| BM-derived germ cell candidates – Oct-4<sup>+</sup> Mvh<sup>+</sup> Dazl<sup>+</sup> Stella<sup>+</sup> cells present in BM that may affect the recurrence of oogenesis in mice sterilized by chemotherapy. | [70, 71] |
| BM-derived male germ cells – Oct-4<sup>+</sup> Mvh<sup>+</sup> Stella<sup>+</sup> cells isolated as Stra8–GFP cells from bone marrow of Stra8–GFP transgenic mice. These murine bone marrow-derived cells express several molecular markers of spermatogonial stem cells and spermatogonia. | [72] |
| Chicken BM-derived precursors of male germ cells – GFP<sup>+</sup> transgenic chicken Oct-4<sup>+</sup> SSEA-1/3/4<sup>+</sup> cells isolated from bone marrow, which give rise to functional sperm after injection into testes. | [73] |
pluri/multipotent differentiation potential (Figure 2) [61, 62]. Further studies, however, are needed to compare these cell types side by side.

BM provides a permissive microenvironment for a variety of stem cells (including, as we envision, VSELs) circulating in PB during embryonic development to promote their homing to this organ. Molecular analysis of gene libraries established from VSELs revealed that, despite a similar small size, primitive morphology, and expression of surface markers that allow for their purification (Sca-1^+ Lin^- CD45^-), these cells are, in fact, somewhat heterogeneous [63]. We found at least three different types of libraries generated from single, sorted VSELs, and some of these libraries exhibited a strong epiblast- or PGC-like gene expression pattern. In support of such a connection, we observed that murine BM-derived VSELs express several genes that are characteristic of epiblast SCs (Gbx2, Fgf5, and Nodal) and, more importantly, of germline specification and migrating PGCs (Stella, Prdm14, Fragilis, Blimp1, Nanos3, and Dnd1) [64, 65]. The expression of some of these crucial genes has subsequently been confirmed by demonstrating the presence of transcriptionally active promoters in these genes. Importantly, we recently observed that BM-residing VSELs respond in vivo to stimulation by pituitary

**Figure 2** Adult bone marrow as a home for various stem cells. We propose that VSELs are primitive, small, dormant, stem cells that, upon proper activation, give rise to other, larger multi/pluripotent stem cells identified by other investigators in hematopoietic tissues and may also give rise to hematopoietic/stem progenitor cells, mesenchymal stem cells, and endothelial progenitor cells. Abbreviations: VSEL, very small embryonic-like stem cell; HSC, hematopoietic stem cell; MASC, multipotent adult stem cell; MIAMI, marrow-isolated adult multilineage-inducible cell; MAPC, multipotent adult progenitor cell; EPC, endothelial progenitor cell.
and gonadal SexHs and begin to accumulate BrdU [21]. Furthermore, gene expression analysis and immunohistochemical staining confirm that these cells express SexH receptors [21].

Although cells morphologically and phenotypically similar to bone marrow VSELs were found in other tissues, adult BM-residing VSELs probably migrate during development, along with HSCs from sites where fetal hematopoiesis is initiated, to fetal liver and subsequently adult BM [66]. In Table 1, reports on early-development stem cells isolated from adult tissues that express germline markers are listed [67–73], but their relationship to VSELs requires further study. Nevertheless, these observations support the concept that developmentally early stem cells from embryogenesis could be deposited in adult tissues and that there exists in the stem cell compartment a stem cell continuum beginning with embryonic development and extending into adulthood [24].

Question 3 – The Role of Parentally Imprinted Genes in Maintaining the Quiescence of Developmentally Early Adult Stem Cells

As discussed above, evidence has accumulated that adult tissues contain certain early-development stem cells that are endowed with broad trans-germlayer differentiation and multi/pluripotential—for example, VSELs. Nevertheless, to call a given stem cell “pluripotent” requires satisfying both in vitro and in vivo criteria. For in vitro criteria, a pluripotent stem cell candidate has to show undifferentiated morphology, euchromatin, and a high nuclear/cytoplasmic ratio. Such cells should also express markers of pluripotency, such as Oct-4, Nanog, and SSEA, and exhibit bivalent domains in the promoters of genes encoding important developmental, homeobox-containing transcription factors, and female pluripotent stem cells should reactivate the X chromosome. Moreover, such cells should differentiate in appropriate culture conditions into cells from all three germ layers (meso-, ecto-, and endoderm). On the other hand, in vivo criteria for pluripotent stem cells include the ability to complement blastocyst development and grow teratomas in an in vivo assay after injection of these cells into immunodeficient mice.

VSELs fulfill the above-listed in vitro criteria, despite the fact that they are highly quiescent in culture, and special conditions are needed to differentiate them into various lineages [61, 62, 74–80]. However, VSELs do not fulfill the in vivo criteria, as they do not complete blastocyst development and do
not grow teratomas [25, 81]. The reason for quiescence of these cells is the modification of expression of certain parentally imprinted genes. Overall, there are \(\sim 50-100\) paternally imprinted genes in the mammalian genome (expressed from the maternal or paternal chromosome only) that play an important role in embryonal development, and some of them, for example the tandem gene insulin-like growth factor 2 \((Igf2)\)–\(H19\), are of particular importance for the totipotential state of the zygote, embryogenesis, fetal growth, and pluripotency of developmentally early stem cells [26, 82–84].

To explain the developmental role of parentally imprinted genes, mammalian development requires proper gene dosage of these genes, which is enabled by their imprinting, so that a single parental allele (maternal or paternal) is expressed in the cell. Therefore, genomic imprinting is an epigenetic program that ensures the parent-of-origin-specific monoallelic transcription of imprinted genes and results in intracellular expression of imprinted genes from only one of the two paternal chromosomes—derived either from the mother or the father [85]. The epigenetics behind expression of imprinted genes is based on the imposition of epigenetic marks by DNA methylation within differentially methylated regions (DMRs), which are CpG-rich cis-elements within their loci [26, 82–84]. These epigenetic marks imposed on DMRs in the female germline act on the promoters of imprinted genes, which results in the heritable repression of the maternal chromosomes. By contrast, the imposition of epigenetic marks by methylation of the chromosomes in the male germline does not occur at the promoters but rather within the intergenic regions (e.g., between the tandem genes at the \(Igf2\)–\(H19\) locus, as shown by black lollypops in Figure 3).

Figure 3A shows that expression of \(Igf2\) and \(H19\) genes is regulated by a distal enhancer. Since maternal imprinting at the DMR for this tandem gene is erased (open lollypops) at the maternal (M) chromosome, this site binds CTCF protein (insulator), which forms a physical barrier between \(Igf2\) and \(H19\) and thereby prevents the distal enhancer from activating transcription of \(Igf2\) from the maternal allele. By contrast, the DMR region at the paternal chromosome (P) is methylated (black lollypops), and CTCF cannot bind to the DNA. Thus, the distal enhancer activates transcription of \(Igf2\) from the paternal allele.

While \(Igf2\) promotes proliferation, \(H19\) gives rise to non-coding mRNA that is spliced into several miRNAs that negatively affect cell proliferation. As the result of normal, balanced paternal imprinting in cell nuclei, there is balanced expression of \(Igf2\) mRNA from paternal and \(H19\) mRNA from the maternal chromosome [86].
Figure 3  Regulation of expression of the Igf2–H19 tandem gene. Panel A. The Igf2 and H19 coding regions are separated by a differentially methylated region (DMR) that is unmethylated (open lollypops) on the maternal chromosome (M) and methylated (filled lollypops) on the paternal chromosome (P). Expression of both genes is regulated by a 3’ distal enhancer depicted in green. Since the DMR is unmethylated on the maternal chromosome, it binds CTCF, and this prevents activation of the Igf2 promoter by the distal enhancer. As a result, only H19 mRNA is transcribed from the maternal chromosome (red arrow). By contrast, methylation of the DMR on the paternal chromosome prevents binding of the CTCF insulator protein and allows activation of the Igf2 promoter by the distal enhancer and transcription of Igf2 mRNA from the paternal chromosome (red arrow). Normal somatic imprinting observed in all somatic cells results in properly balanced expression of Igf2 from the paternal chromosome and H19 from the maternal chromosome. Panel B. Erasure of imprinting at the Igf2–H19 locus, as seen in PGCs and VSELs, leads to a situation in which DMRs on the maternal and paternal chromosomes both bind CTCF, and the 3’ distal enhancer activates transcription of only H19 from both chromosomes. Therefore, erasure of imprinting at the Igf2–H19 locus leads to overexpression of proliferation-inhibiting H19 mRNA.

As mentioned above, erasure of genomic imprints is one of the crucial mechanisms that prevents PGCs and VSELs from proliferation, blastocyst complementation, and teratoma formation [25, 81]. As a result of erasure of the DMR at the Igf2–H19 locus (Figure 3B), both maternal and paternal DMRs bind insulator protein, and the distal enhancer activates transcription of H19 from both parental alleles. Cells affected by this epigenetic mechanism do not
express insulin-like growth factor 2 (IGF-2), which promotes cell proliferation, and overexpress noncoding H19 mRNA, thereby negatively affecting cell proliferation. This epigenetic change in expression at the Igf2–H19 locus explains why PGCs and VSELs remain quiescent [25, 87].

To get a full picture of these epigenetic changes, in addition to erasure of imprinting at the Igf2–H19 locus, murine BM-residing VSELs also erase the paternally methylated imprints within the DMRs for RasGrf1. In parallel, they hypermethylate the maternally methylated DMR for the insulin-like growth factor 2 receptor gene (IGF2R). As a result of these changes, VSELs, like PGCs, are resistant to insulin/insulin-like growth factor signaling. Specifically, the changes in expression of imprinted genes lead to perturbation of insulin/insulin-like growth factor signaling by downregulation of i) IGF-2, which is an autocrine factor involved in proliferation of VSELs, and ii) RasGRF1, which is a GTP-exchange factor (GEF) crucial for signaling from the activated insulin-like growth factor 1 receptor (IGF-1R) and the insulin receptor (InsR). In addition, since the IGF2R serves as a decoy receptor that prevents IGF-2 from binding to IGF-1R, hyperemethylation of the DMRs on the maternal chromosome encoding IGF-2R, which leads to overexpression of this gene, has an additional negative affect on IGF-2 signaling in VSELs [88]. Our recent data suggest that a very similar mechanism is also most likely responsible for the quiescent state of human VSELs not only in bone marrow but also in adult tissues. This mechanism, characteristic of PGCs and VSELs [25, 87], keeps them in a quiescent state. As we have shown, the finding that the most primitive stem cells in adult bone marrow are endowed with long-term reconstituting potential [25] has recently been confirmed by another group [89].

In sum, these epigenetic modifications of imprinted loci (including Igf2–H19, RasGRF1, and IGF2R) hampers efficient expansion of these cells in ex vivo cultures but, on the other hand, prevents them from undergoing uncontrolled proliferation and teratoma formation in vivo.

Conclusions

Evidence has accumulated for the existence of a developmental link between germline cells and hematopoiesis, shedding new light on the developmental hierarchy of the stem cell compartment in adult tissues. As reported, several pituitary and gonadal SexHs directly stimulate the expansion of HSCs in BM, and, vice versa, germline-derived cells respond to stimulation by EPO [37]. These observations also have important practical implications: i) pituitary
gonadal hormones could be employed in selected cases of BM failure to stimulate hematopoiesis and ii) erythropoietin treatment (e.g., for anemia after chemotherapy) should be avoided in patients with germline malignancies.

Evidence has also accumulated that adult tissues contain rare stem cells from early development that show broad cross-germline differentiation potential. These cells have been described by different names, and most likely some of them are overlapping stem cell populations at different levels of tissue specification [67–73].

Our group has identified VSELs in adult tissues and demonstrated that epigenetic modification of certain imprinted genes in these cells plays a crucial role in controlling their proliferation. On the other hand, reversal of this imprinting mechanism will be crucial to employing these cells in regenerative medicine. Currently, we are testing whether downregulation of the expression of $H19$ enhances VSEL expansion, as has recently been demonstrated for PSCs derived by parthenogenesis [90].

**Acknowledgements**

This work was supported by NIH grants 2R01 DK074720 and R01HL112788 and the Stella and Henry Endowment to MZR.

**References**

[1] A. P. Beltrami, D. Cesselli, N. Bergamin et al. “Multipotent cells can be generated in vitro from several adult human organs (heart, liver, and bone marrow).” *Blood* **110**, 3438–3446. (2007).

[2] G. D’Ippolito, S. Diabira, G. A. Howard et al. “Marrow-isolated adult multilineage inducible (MIAMI) cells, a unique population of postnatal young and old human cells with extensive expansion and differentiation potential.” *J. Cell Sci.* **117**(Pt. 14), 2971–2981. (2004).

[3] G. Kogler, S. Sensken, J. A. Airey et al. “A new human somatic stem cell from placental cord blood with intrinsic pluripotent differentiation potential.” *J. Exp. Med.* **200**, 123–135. (2004).

[4] Y. Jiang, B. N. Jahagirdar, R. L. Reinhardt et al. “Pluripotency of mesenchymal stem cells derived from adult marrow.” *Nature* **418**, 41–49. (2002).

[5] T. Y. Ling, M. D. Kuo, C. L. Li et al. “Identification of pulmonary Oct-4+ stem/progenitor cells and demonstration of their susceptibility
to SARS coronavirus (SARS-CoV) infection in vitro.” Proc. Natl. Acad. Sci. U.S.A. 103, 9530–9535. (2006).
[6] B. E. Petersen, W. C. Bowen, K. D. Patrene et al. “Bone marrow as a potential source of hepatic oval cells.” Science 284, 1168–1170. (1999).
[7] F. Anjos-Afonso, and D. Bonnet. “Nonhematopoietic/endothelial SSEA-1+ cells define the most primitive progenitors in the adult murine bone marrow mesenchymal compartment.” Blood 109, 1298–1306. (2007).
[8] H. Yu, D. Fang, S. M. Kumar et al. “Isolation of a novel population of multipotent adult stem cells from human hair follicles.” Am. J. Pathol. 168, 1879–1888. (2006).
[9] L. Li, and H. Clevers. “Coexistence of quiescent and active adult stem cells in mammals.” Science 327, 542–545. (2010).
[10] T. Asahara, T. Murohara, A. Sullivan et al. “Isolation of putative progenitor endothelial cells for angiogenesis.” Science 275, 964–967. (1997).
[11] S. Wakao, M. Kitada, Y. Kuroda et al. “Multilineage-differentiating stress-enduring (Muse) cells are a primary source of induced pluripotent stem cells in human fibroblasts.” Proc. Natl. Acad. Sci. U.S.A. 108, 9875–9880. (2011).
[12] M. Serafini, S. J. Dylla, M. Oki et al. “Hematopoietic reconstitution by multipotent adult progenitor cells: precursors to long-term hematopoietic stem cells.” J. Exp. Med. 204, 129–139. (2007).
[13] D. J. Prockop. “Marrow stromal cells as stem cells for nonhematopoietic tissues.” Science 276, 71–74. (1997).
[14] M. Kritzenberger, and K. H. Wrobel. “Histochemical in situ identification of bovine embryonic blood cells reveals differences to the adult haematopoietic system and suggests a close relationship between haematopoietic stem cells and primordial germ cells.” Histochem Cell Biol. 121, 273–289. (2004).
[15] T. Ohtaka, Y. Matsui, and M. Obinata. “Hematopoietic development of primordial germ cell-derived mouse embryonic germ cells in culture.” Biochem. Biophys. Res. Commun. 260, 475–482. (1999).
[16] I. N. Rich. “Primordial germ cells are capable of producing cells of the hematopoietic system in vitro.” Blood 86, 463–472. (1995).
[17] A. Saito, K. Watanabe, T. Kusakabe et al. “Mediastinal mature teratoma with coexistence of angiosarcoma, granulocytic sarcoma and a hematopoietic region in the tumor: a rare case of association between hematological malignancy and mediastinal germ cell tumor.” Pathol. Int. 48, 749–753. (1998).
[18] D. Nakada, H. Oguro, B. P. Levi et al. “Oestrogen increases haematopoietic stem-cell self-renewal in females and during pregnancy.” *Nature* **505**, 555–558. (2014).

[19] E. Carreras, S. Turner, V. Paharkova-Vatchkova et al. “Estradiol acts directly on bone marrow myeloid progenitors to differentially regulate GM-CSF or Flt3 ligand-mediated dendritic cell differentiation.” *J. Immunol.* **180**, 727–738. (2008).

[20] M. Maggio, P. J. Snyder, G. P. Ceda et al. “Is the haematopoietic effect of testosterone mediated by erythropoietin? The results of a clinical trial in older men.” *Andrology* **1**, 24–28. (2013).

[21] K. S. Mierzejewska, E. Borkowska S. J. Suszynska, M. Maj, M. Ratajczak, J. Kucia, M. Ratajczak, M. Z. “Novel In Vivo Evidence That Not Only Androgens But Also Pituitary Gonadotropins and Prolactin Directly Stimulate Marine Bone Marrow Stem Cells – Implications For Potential Treatment Strategies In Aplastic Anemias,” in 55th ASH Annual Meeting and Exposition. New Orleans, LA. (2013).

[22] M. Z. Ratajczak, M. Majka, M. Kucia et al. “Expression of functional CXCR4 by muscle satellite cells and secretion of SDF-1 by muscle-derived fibroblasts is associated with the presence of both muscle progenitors in bone marrow and hematopoietic stem/progenitor cells in muscles.” *Stem Cells* **21**, 363–371. (2003).

[23] M. Z. Ratajczak, M. Kucia, R. Reca et al. “Stem cell plasticity revisited: CXCR4-positive cells expressing mRNA for early muscle, liver and neural cells ‘hide out’ in the bone marrow.” *Leukemia* **18**, 29–40. (2004).

[24] M. Z. Ratajczak, B. Machalinski, W. Wojakowski et al. “A hypothesis for an embryonic origin of pluripotent Oct-4(+) stem cells in adult bone marrow and other tissues”, *Leukemia* **21**, 860–867. (2007).

[25] D. M. Shin, E. K. Zuba-Surma, W. Wu et al. “Novel epigenetic mechanisms that control pluripotency and quiescence of adult bone marrow-derived Oct4(+) very small embryonic-like stem cells.” *Leukemia* **23**, 2042–2051. (2009).

[26] W. Reik, and J. Walter. “Genomic imprinting: parental influence on the genome.” *Nat. Rev. Genet.* **2**, 21–32. (2001).

[27] M. Pick, Y. Stelzer, O. Bar-Nur et al. “Clone- and gene-specific aberrations of parental imprinting in human induced pluripotent stem cells.” *Stem Cells* **27**, 2686–2690. (2009).

[28] A. McLaren. “Development of primordial germ cells in the mouse.” *Andrologia* **24**, 243–247. (1992).
[29] A. McLaren. “Primordial germ cells in the mouse.” *Dev. Biol.* 262, 1–15. (2003).

[30] K. Molyneaux, and C. Wylie. “Primordial germ cell migration.” *Int. J. Dev. Biol.* 48, 537–544. (2004).

[31] M. P. De Miguel, F. Arnalich Montiel, P. Lopez Iglesias et al. “Epiblast-derived stem cells in embryonic and adult tissues.” *Int. J. Dev. Biol.* 53, 1529–1540. (2009).

[32] H. K. Mikkola, and S. H. Orkin. “The journey of developing hematopoietic stem cells.” *Development* 133, 3733–3744. (2006).

[33] J. Palis. “Primitive and definitive erythropoiesis in mammals.” *Front. Physiol.* 5:3. (2014).

[34] A. Ivanovs, S. Rybtsov, L. Welch et al. “Highly potent human hematopoietic stem cells first emerge in the intraembryonic aorta-gonad-mesonephros region.” *J. Exp. Med.* 208, 2417–2427. (2011).

[35] J. Zhang, W. L. Tam, G. Q. Tong et al. “Sall4 modulates embryonic stem cell pluripotency and early embryonic development by the transcriptional regulation of Pou5f1.” *Nat. Cell Biol.* 8, 1114–1123. (2006).

[36] C. Gao, N. R. Kong, A. Li et al. “SALL4 is a key transcription regulator in normal human hematopoiesis.” *Transfusion* 53, 1037–1049. (2013).

[37] M. Suszynska, A. Poniewierska-Baran, P. Gunjal et al. “Expression of the erythropoietin receptor by germline-derived cells – further support for a potential developmental link between the germline and hematopoiesis.” *J. Ovarian. Res.* 7, 66. (2014).

[38] K. Woodruff, N. Wang, W. May et al. “The clonal nature of mediastinal germ cell tumors and acute myelogenous leukemia. A case report and review of the literature.” *Cancer Genet. Cytogenet.* 79, 25–31. (1995).

[39] R. S. Chaganti, M. Ladanyi, F. Samaniego et al. “Leukemic differentiation of a mediastinal germ cell tumor.” *Genes Chromosomes Cancer* 1, 83–87. (1989).

[40] C. R. Nichols, R. Hoffman, L. H. Einhorn et al. “Hematologic malignancies associated with primary mediastinal germ-cell tumors.” *Ann. Int. Med.* 102, 603–609. (1985).

[41] M. Yoshimoto, T. Heike, H. Chang et al. “Bone marrow engraftment but limited expansion of hematopoietic cells from multipotent germline stem cells derived from neonatal mouse testis.” *Exp. Hematol.* 37, 1400–1410. (2009).

[42] Y. Miwa, T. Atsumi, N. Imai et al. “Primitive erythropoiesis of mouse teratocarcinoma stem cells PCC3/A/1 in serum-free medium.” *Development* 111, 543–549. (1991).
[43] D. Orlic, J. Kajstura, S. Chimenti et al. “Bone marrow cells regenerate infarcted myocardium.” *Nature* **410**, 701–705. (2001).

[44] M. A. LaBarge, and H. M. Blau. “Biological progression from adult bone marrow to mononucleate muscle stem cell to multinucleate muscle fiber in response to injury.” *Cell* **111**, 589–601. (2002).

[45] J. R. Sanchez-Ramos. “Neural cells derived from adult bone marrow and umbilical cord blood.” *J. Neurosci. Res.* **69**, 880–893. (2002).

[46] E. L. Herzog, L. Chai, and D. S. Krause. “Plasticity of marrow-derived stem cells.” *Blood* **102**, 3483–3493. (2003).

[47] D. C. Hess, T. Abe, W. D. Hill et al. “Hematopoietic origin of microglial and perivascular cells in brain.” *Exp. Neurol.* **186**, 134–144. (2004).

[48] S. Corti, F. Locatelli, C. Donadoni et al. “Neuroectodermal and microglial differentiation of bone marrow cells in the mouse spinal cord and sensory ganglia.” *J. Neurosci. Res.* **70**, 721–733. (2002).

[49] N. Terada, T. Hamazaki, M. Oka et al. “Bone marrow cells adopt the phenotype of other cells by spontaneous cell fusion.” *Nature* **416**, 542–545. (2002).

[50] G. Vassilopoulos, and D. W. Russell. “Cell fusion: an alternative to stem cell plasticity and its therapeutic implications.” *Curr. Opin. Genet. Dev.* **13**, 480–485. (2003).

[51] E. W. Scott. “Stem cell plasticity or fusion: two approaches to targeted cell therapy.” *Blood Cells Mol. Dis.* **32**, 65–67. (2004).

[52] L. M. Eisenberg, and C. A. Eisenberg. “Stem cell plasticity, cell fusion, and transdifferentiation.” *Birth Defects Res. C Embryo Today* **69**, 209–218. (2003).

[53] M. Kucia, M. Halasa, M. Wysoczynski et al. “Morphological and molecular characterization of novel population of CXCR4+ SSEA-4+ Oct-4+ very small embryonic-like cells purified from human cord blood: preliminary report.” *Leukemia* **21**, 297–303. (2007).

[54] M. P. Vacanti, A. Roy, J. Cortiella et al. “Identification and initial characterization of spore-like cells in adult mammals.” *J. Cell Biochem.* **80**, 455–460. (2001).

[55] K. Le Blanc, and M. Pittenger. “Mesenchymal stem cells: progress toward promise.” *Cytoteraphy* **7**, 36–45. (2005).

[56] Y. Kuroda, S. Wakao, M. Kitada et al. “Isolation, culture and evaluation of multilineage-differentiating stress-enduring (Muse) cells.” *Nat. Protoc.* **8**, 1391–1415. (2013).

[57] D. Cesselli, A. P. Beltrami, S. Rigo et al. “Multipotent progenitor cells are present in human peripheral blood.” *Circ. Res.* **104**, 1225–1234. (2009).
[58] S. M. Guthrie, L. M. Curtis, R. N. Mames et al. “The nitric oxide pathway modulates hemangioblast activity of adult hematopoietic stem cells.” Blood 105, 1916–1922. (2005).

[59] S. Parte, D. Bhartiya, J. Telang et al. “Detection, characterization, and spontaneous differentiation in vitro of very small embryonic-like putative stem cells in adult mammalian ovary.” Stem Cells Dev. 20, 1451–1464. (2011).

[60] D. Bhartiya, S. Kasiviswananthan, and A. Shaikh. “Cellular origin of testis-derived pluripotent stem cells: a case for very small embryonic-like stem cells.” Stem Cells Dev. 21, 670–674. (2012).

[61] R. S. Taichman, Z. Wang, Y. Shiozawa et al. “Prospective identification and skeletal localization of cells capable of multilineage differentiation in vivo.” Stem Cells Dev. 19, 1557–1570. (2010).

[62] A. M. Havens, Y. Shiozawa, Y. Jung et al. “Human very small embryonic-like cells generate skeletal structures, in vivo.” Stem Cells Dev. 22, 622–630. (2013).

[63] D. M. Shin, R. Liu, W. Wu et al. “Global gene expression analysis of very small embryonic-like stem cells reveals that the Ezh2-dependent bivalent domain mechanism contributes to their pluripotent state.” Stem Cells Dev. 21, 1639–1652. (2012).

[64] D. M. Shin, R. Liu, I. Klich et al. “Molecular characterization of isolated from murine adult tissues very small embryonic/epiblast like stem cells (VSELs).” Mol. Cells. 29, 533–538. (2010).

[65] D. M. Shin, R. Liu, I. Klich et al. “Molecular signature of adult bone marrow-purified very small embryonic-like stem cells supports their developmental epiblast/germ line origin.” Leukemia 24, 1450–1461. (2010).

[66] M. Kucia, W. Wu, and M. Z. Ratajczak. “Bone marrow-derived very small embryonic-like stem cells: their developmental origin and biological significance.” Dev. Dyn. 236, 3309–3320. (2007).

[67] P. W. Dyce, J. Liu, C. Tayade et al. “In vitro and in vivo germ line potential of stem cells derived from newborn mouse skin.” PLoS ONE 6: e20339. (2011).

[68] S. H. Song, B. M. Kumar, E. J. Kang et al. “Characterization of porcine multipotent stem/stromal cells derived from skin, adipose, and ovarian tissues and their differentiation in vitro into putative oocyte-like cells.” Stem Cells Dev. 20, 1359–1370. (2011).
[69] R. Shirazi, A. H. Zarnani, M. Soleimani et al. “BMP4 can generate primordial germ cells from bone-marrow-derived pluripotent stem cells.” Cell. Biol. Int. 36, 1185–1193. (2012).

[70] J. Johnson, J. Bagley, M. Skaznik-Wikel et al. “Oocyte generation in adult mammalian ovaries by putative germ cells in bone marrow and peripheral blood.” Cell 122, 303–315. (2005).

[71] K. Selesniemi, H. J. Lee, T. Niikura et al. “Young adult donor bone marrow infusions into female mice postpone age-related reproductive failure and improve offspring survival.” Aging (Albany NY) 1, 49–57. (2009).

[72] K. Nayernia, J. H. Lee, N. Drusenheimer et al. “Derivation of male germ cells from bone marrow stem cells.” Lab. Invest. 86, 654–663. (2006).

[73] Y. T. Heo, S. H. Lee, J. H. Yang et al. “Bone marrow cell-mediated production of transgenic chickens.” Lab. Invest. 91, 1229–1240. (2011).

[74] S. H. Kassmer, H. Jin, P. X. Zhang et al. “Very small embryonic-like stem cells from the murine bone marrow differentiate into epithelial cells of the lung.” Stem Cells 31, 2759–2766. (2013).

[75] J. Ratajczak, M. Wysoczynski, E. Zuba-Surma et al. “Adult murine bone marrow-derived very small embryonic-like stem cells differentiate into the hematopoietic lineage after coculture over OP9 stromal cells.” Exp. Hematol. 39, 225–237. (2011).

[76] J. Ratajczak, E. Zuba-Surma, I. Klich et al. “Hematopoietic differentiation of umbilical cord blood-derived very small embryonic/epiblast-like stem cells.” Leukemia 25, 1278–1285. (2011).

[77] B. Dawn, S. Tiwari, M. J. Kucia et al. “Transplantation of bone marrow-derived very small embryonic-like stem cells attenuates left ventricular dysfunction and remodeling after myocardial infarction.” Stem Cells 26, 1646–1655. (2008).

[78] E. K. Zuba-Surma, Y. Guo, H. Taher et al. “Transplantation of expanded bone marrow-derived very small embryonic-like stem cells (VSEL-SCs) improves left ventricular function and remodeling after myocardial infarction”, J. Cell Mol. Med. 15, 1319–1328. (2011).

[79] J. H. Wu, H. J. Wang, Y. Z. Tan et al. “Characterization of rat very small embryonic-like stem cells and cardiac repair after cell transplantation for myocardial infarction.” Stem Cells Dev. 21, 1367–1379. (2012).

[80] Z. Chen, X. Lv, H. Dai et al. “Hepatic Regenerative Potential of Mouse Bone Marrow Very Small Embryonic-Like Stem Cells.” J. Cell Physiol. (2014).
[81] M. Z. Ratajczak, D. M. Shin, R. Liu et al. “Very small embryonic/epiblast-like stem cells (VSELs) and their potential role in aging and organ rejuvenation—an update and comparison to other primitive small stem cells isolated from adult tissues.” *Aging (Albany NY)* 4, 235–246. (2012).

[82] M. Pannetier, and R. Feil. “Epigenetic stability of embryonic stem cells and developmental potential.” *Trends Biotechnol.* 25, 556–562. (2007).

[83] K. Delaval, and R. Feil. “Epigenetic regulation of mammalian genomic imprinting.” *Curr. Opin. Genet. Dev.* 14, 188–195. (2004).

[84] M. S. Bartolomei, and A. C. Ferguson-Smith. “Mammalian genomic imprinting.” *Cold Spring Harb Perspect. Biol.* 3. (2011).

[85] R. N. Plasschaert, and M. S. Bartolomei. “Genomic imprinting in development, growth, behavior and stem cells.” *Development* 141, 1805–1813. (2014).

[86] A. Keniry, D. Oxley, P. Monnier et al. “The H19 lincRNA is a developmental reservoir of miR-675 that suppresses growth and Igf1r.” *Nat. Cell Biol.* 14, 659–665. (2012).

[87] G. Durcova-Hills, F. Tang, G. Doody et al. “Reprogramming primordial germ cells into pluripotent stem cells.” *PLoS ONE* 3:e3531. (2008).

[88] M. Kucia, M. Masternak, R. Liu et al. “The negative effect of prolonged somatotrophic/insulin signaling on an adult bone marrow-residing population of pluripotent very small embryonic-like stem cells (VSELs).” *Age (Dordr)* 35, 315–330. (2013).

[89] A. Venkatraman, X. C. He, J. L. Thorvaldsen et al. “Maternal imprinting at the H19-Igf2 locus maintains adult haematopoietic stem cell quiescence.” *Nature* 500, 345–349. (2013).

[90] T. Kono, Y. Obata, Q. Wu et al. “Birth of parthenogenetic mice that can develop to adulthood.” *Nature* 428, 860–864. (2004).
Biographies

**M. Z. Ratajczak** is Professor of Medicine, the Henry M. and Stella M. Hoenig Endowed Chair in Cancer Biology and the Director of the Developmental Biology Research Program at the University of Louisville’s James Graham Brown Cancer Center. Dr. Ratajczak earned his M.D. at the Pomeranian Medical University and his Ph.D. and D.Sci. and habilitation at the Center for Clinical and Experimental Medicine of Polish Academy of Sciences in Warsaw, Poland. He is an internationally known specialist in the field of adult stem cell biology. His 2005 discovery of embryonic-like stem cells in adult bone marrow tissues has the potential to revolutionize the field of regenerative medicine.

**G. Schneider** obtained M.Sc. degree in Biotechnology at West Pomeranian University in Szczecin, Poland and received her Ph.D. in Biology at Nencki Institute of Experimental Biology PAS, Warsaw, Poland in 2009. Currently she is a Postdoctoral Fellow in the group of Prof. Mariusz Z Ratajczak at University of Louisville’s James Graham Brown Cancer Center. Her recent
research focuses on the mechanism of cancer metastasis and epigenetic modification of imprinted genes in normal and malignant cells.

M. Suszynska received her M.Sc degree in Biotechnology in 2009. She obtained Ph.D. degree in Medical Biology in 2015, under supervision of Prof. Mariusz Z. Ratajczak, from Pomeranian Medical University, Poland. Since 2012 she is working at Stem Cell Institute at the University of Louisville, USA as a researcher. Her research activities are currently focused on adult stem cell biology.
